Overview
Martha Dietzel practices practicing medicine in Muenster, Germany.
Her clinical expertise encompasses Age-Related Macular Degeneration (ARMD) and Late-Onset Retinal Degeneration.
She is actively involved in clinical research, co-authoring 11 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Martha Dietzel
Is Martha Dietzel a top-rated expert for Age-Related Macular Degeneration (ARMD)?
MediFind is an objective health platform that identifies experts based on real-world data. Martha Dietzel is classified as an Experienced expert for Age-Related Macular Degeneration (ARMD), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Martha Dietzel participate in research or clinical trials?
Yes. Martha Dietzel has published 11 articles and abstracts on conditions like Age-Related Macular Degeneration (ARMD). You can view a list of Martha Dietzel's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Age-Related Macular Degeneration (ARMD)Ms. Dietzel isExperienced. Learn about Age-Related Macular Degeneration (ARMD).
- Late-Onset Retinal DegenerationMs. Dietzel isExperienced. Learn about Late-Onset Retinal Degeneration.